The percentages of patients with ANM (53.89% vs. 39.13%, p = 0.005), HER2 overexpression (p < 0.001), and P53 mutation (p = 0.015) were higher in the MC group. This evidence concerns the gene ERBB2 and nemaline myopathy 5.